Precision Medicine in Oncology®

Many physicians are excited by the possibility of following the evolving story of their patients’ cancer no longer through images including PET scans, but through changes in the molecular phenotype of their patients’ tumors.

Next-generation sequencing efforts focusing on the most common form, head and neck squamous cell carcinoma, are illuminating the hidden complexities of its genome.

Treatment with gefitinib failed to show noninferiority compared with erlotinib for patients with pretreated non–small cell lung cancer.

Faisal Musa, MD, reviews the case of a patient with large granulocytic leukemia and discusses why collaborating with the patient’s pathologist was so important to her diagnosis.

George Demetri, MD, discusses the impact of the eribulin’s FDA approval, what oncologists can learn from studying liposarcoma, and the challenges that come with treating a rare disease.

Combining 3 markers of homologous recombination deficiency significantly improved prediction of outcome of platinum-based treatment of ovarian cancer compared with the individual markers, a retrospective analysis of tissue samples showed.

Patients with advanced ovarian cancer harboring mutations in homologous recombination (HR) genes, including BRCA1/2, had improved survival outcomes versus patients without HR mutations.